QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-reinstates-buy-on-sensei-biotherapeutics-announces-4-price-target

Citigroup analyst Samantha Semenkow reinstates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and announces $4 price target.

 hc-wainwright--co-reiterates-buy-on-sensei-biotherapeutics-maintains-4-price-target

HC Wainwright & Co. analyst Edward White reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and maintains $4 pri...

 stephens--co-reiterates-overweight-on-sensei-biotherapeutics-maintains-5-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight and maintains ...

 stephens--co-initiates-coverage-on-sensei-biotherapeutics-with-overweight-rating-announces-price-target-of-5

Stephens & Co. analyst Sudan Loganathan initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight rat...

 sensei-biotherapeutics-to-present-topline-clinical-data-from-the-sns-101-phase-i-dose-escalation-study-at-the-2024-asco-annual-meeting

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development o...

 sensei-biotherapeutics-announces-nature-communications-publication-describing-mechanism-of-action-of-sns-101-selectively-targeting-the-active-form-of-vista-within-the-tumor-microenvironment

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development o...

 sensei-biotherapeutics-cfo-to-resign-all-positions-with-co-effective-april-10

-SEC Filing

 sensei-biotherapeutics-fy-eps-122-up-from-158-yoy-2023-year-end-cash-cash-equivalents-and-marketable-securities-of-658m-is-expected-to-provide-cash-runway-into-fourth-quarter-of-2025

Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(1.22) per share. This is a 22.78 percent increase over loss...